http://www.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Tue, 20 Oct 2026 09:24:38 -0400 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://www.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/Analyst+Comments/Truist+Securities+Reiterates+Buy+Rating+on+Scholar+Rock+%28SRRK%29+After+KOL+Feedback/27208097.html <p>Truist Securities analyst Srikripa Devarakonda reiterated a Buy rating and $77.00 price target on Scholar Rock (NASDAQ: SRRK).</p><p>The analyst commented: "SMA KOLs say 80% pts interested in Isembyld, expect 50-60% pts to be on drug in 5yrs; fractures not limiting; We reiterate Buy on SRRK after KOL feedback supporting broad Isembyld uptake, with two KOLs guiding to ~60% and ~50% SMA patient penetration in five years. KOLs validated SAPPHIRE, highlighting ~33% responder rate at >=3 points and real function (rolling, feeding, sitting). Both would prescribe broadly, favoring earlier patients, with ~80% patient interest cited. KOLs to watch fracture risk but http://www.streetinsider.com/Analyst+Comments/Truist+Securities+Reiterates+Buy+Rating+on+Scholar+Rock+%28SRRK%29+After+KOL+Feedback/27208097.html Tue, 20 Oct 2026 09:24:38 -0400 SRRK http://www.streetinsider.com/Press+Releases/Scholar+Rock+to+Report+Third+Quarter+2026+Financial+Results+on+November+10%2C+2026/27206783.html <p> CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Scholar Rock (NASDAQ: SRRK) today announced that it will report third quarter 2026 financial results on Tuesday, November 10, 2026, before the financial markets open. </p><p> The Company will host a conference call and webcast with Scholar Rock management at 8:00 a.m. ET. To access the live audio webcast, please go to “Events and Presentations” in the Investors section of the Scholar Rock website at <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=http%3A%2F%2Finvestors.scholarrock.com&amp;esheet=54622970&amp;newsitemid=20261020593796&amp;lan=en-US&amp;anchor=http%3A%2F%2Finvestors.scholarrock.com&amp;index=1&amp;md5=fd199edd7229ec43269b5c6cf4d8264b" shape="rect">http://investors.scholarrock.com</a>. </p><p> To participate via telephone, please register in advance <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Furldefense.com%2Fv3%2F__https%3A%2Fregister-conf.media-server.com%2Fregister%2FBI4b5fe19155814f04a7c24ad000f34081__%3B%21%21BIxG9zGngU4O%21ijaco7btrdA4OoSHaTUgktZ3ioio6_YJlvcZlT_qyP-bK5cJ3lvFcyd6BFND4hntNcmJYhTu0L3AI7rFhSJGTO6xmGD0lg%24&amp;esheet=54622970&amp;newsitemid=20261020593796&amp;lan=en-US&amp;anchor=here&amp;index=2&amp;md5=c12f5090d50d601a655abcb5105d090d" shape="rect">here</a>. Upon registration, all telephone participants will receive a confirmation email detailing how to join http://www.streetinsider.com/Press+Releases/Scholar+Rock+to+Report+Third+Quarter+2026+Financial+Results+on+November+10%2C+2026/27206783.html Tue, 20 Oct 2026 08:00:00 -0400 SRRK http://www.streetinsider.com/Business+Wire/Scholar+Rock+to+Report+Third+Quarter+2026+Financial+Results+on+November+10%2C+2026/27206783.html <p> CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Scholar Rock (NASDAQ: SRRK) today announced that it will report third quarter 2026 financial results on Tuesday, November 10, 2026, before the financial markets open. </p><p> The Company will host a conference call and webcast with Scholar Rock management at 8:00 a.m. ET. To access the live audio webcast, please go to “Events and Presentations” in the Investors section of the Scholar Rock website at <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=http%3A%2F%2Finvestors.scholarrock.com&amp;esheet=54622970&amp;newsitemid=20261020593796&amp;lan=en-US&amp;anchor=http%3A%2F%2Finvestors.scholarrock.com&amp;index=1&amp;md5=fd199edd7229ec43269b5c6cf4d8264b" shape="rect">http://investors.scholarrock.com</a>. </p><p> To participate via telephone, please register in advance <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Furldefense.com%2Fv3%2F__https%3A%2Fregister-conf.media-server.com%2Fregister%2FBI4b5fe19155814f04a7c24ad000f34081__%3B%21%21BIxG9zGngU4O%21ijaco7btrdA4OoSHaTUgktZ3ioio6_YJlvcZlT_qyP-bK5cJ3lvFcyd6BFND4hntNcmJYhTu0L3AI7rFhSJGTO6xmGD0lg%24&amp;esheet=54622970&amp;newsitemid=20261020593796&amp;lan=en-US&amp;anchor=here&amp;index=2&amp;md5=c12f5090d50d601a655abcb5105d090d" shape="rect">here</a>. Upon registration, all telephone participants will receive a confirmation email detailing how to join http://www.streetinsider.com/Business+Wire/Scholar+Rock+to+Report+Third+Quarter+2026+Financial+Results+on+November+10%2C+2026/27206783.html Tue, 20 Oct 2026 08:00:00 -0400 SRRK http://www.streetinsider.com/Hot+List/U.S.+biotech+SMids%3A+Q3+earnings+preview/27199432.html <p>Citi is out with its preview into Q3 earnings of U.S. Smid biotech stocks, noting that a continued catalyst calendar and business development engagement have kept investor interest high in this part of the market. The firm has shared with investors key catalysts to watch.</p><p>While conversations on large-cap Biopharma tend to have policy and AI in focus, SMids “offer a more direct investment case around clinical data, regulatory progress, and launch execution.”</p><p>Also, while high interest rates are a valuation and financing headwind, the market sees the situation as temporary, which according to Citi, will allow IPO momentum to continue.</p><p>Given this http://www.streetinsider.com/Hot+List/U.S.+biotech+SMids%3A+Q3+earnings+preview/27199432.html Sun, 18 Oct 2026 20:00:00 -0400 ABOS AMLX BNTX FTH JAZZ KNSA KYMR MANE MRNA NAMS NUVB NVAX PTGX SRRK VOR http://www.streetinsider.com/Hot+List+Pro/U.S.+biotech+SMids%3A+Q3+earnings+preview/27199432.html <p>Citi is out with its preview into Q3 earnings of U.S. Smid biotech stocks, noting that a continued catalyst calendar and business development engagement have kept investor interest high in this part of the market. The firm has shared with investors key catalysts to watch.</p><p>While conversations on large-cap Biopharma tend to have policy and AI in focus, SMids “offer a more direct investment case around clinical data, regulatory progress, and launch execution.”</p><p>Also, while high interest rates are a valuation and financing headwind, the market sees the situation as temporary, which according to Citi, will allow IPO momentum to continue.</p><p>Given this http://www.streetinsider.com/Hot+List+Pro/U.S.+biotech+SMids%3A+Q3+earnings+preview/27199432.html Sun, 18 Oct 2026 20:00:00 -0400 ABOS AMLX BNTX FTH JAZZ KNSA KYMR MANE MRNA NAMS NUVB NVAX PTGX SRRK VOR http://www.streetinsider.com/Hot+List/U.S.+biotech+SMids%3A+Q3+earnings+preview/27199432.html <p>Citi is out with its preview into Q3 earnings of U.S. Smid biotech stocks, noting that a continued catalyst calendar and business development engagement have kept investor interest high in this part of the market. The firm has shared with investors key catalysts to watch.</p><p>While conversations on large-cap Biopharma tend to have policy and AI in focus, SMids “offer a more direct investment case around clinical data, regulatory progress, and launch execution.”</p><p>Also, while high interest rates are a valuation and financing headwind, the market sees the situation as temporary, which according to Citi, will allow IPO momentum to continue.</p><p>Given this http://www.streetinsider.com/Hot+List/U.S.+biotech+SMids%3A+Q3+earnings+preview/27199432.html Sun, 18 Oct 2026 20:00:00 -0400 ABOS AMLX BNTX FTH JAZZ KNSA KYMR MANE MRNA NAMS NUVB NVAX PTGX SRRK VOR http://www.streetinsider.com/Hot+List+Pro/U.S.+biotech+SMids%3A+Q3+earnings+preview/27199432.html <p>Citi is out with its preview into Q3 earnings of U.S. Smid biotech stocks, noting that a continued catalyst calendar and business development engagement have kept investor interest high in this part of the market. The firm has shared with investors key catalysts to watch.</p><p>While conversations on large-cap Biopharma tend to have policy and AI in focus, SMids “offer a more direct investment case around clinical data, regulatory progress, and launch execution.”</p><p>Also, while high interest rates are a valuation and financing headwind, the market sees the situation as temporary, which according to Citi, will allow IPO momentum to continue.</p><p>Given this http://www.streetinsider.com/Hot+List+Pro/U.S.+biotech+SMids%3A+Q3+earnings+preview/27199432.html Sun, 18 Oct 2026 20:00:00 -0400 ABOS AMLX BNTX FTH JAZZ KNSA KYMR MANE MRNA NAMS NUVB NVAX PTGX SRRK VOR http://www.streetinsider.com/Hot+List/U.S.+biotech+SMids%3A+Q3+earnings+preview/27199432.html <p>Citi is out with its preview into Q3 earnings of U.S. Smid biotech stocks, noting that a continued catalyst calendar and business development engagement have kept investor interest high in this part of the market. The firm has shared with investors key catalysts to watch.</p><p>While conversations on large-cap Biopharma tend to have policy and AI in focus, SMids “offer a more direct investment case around clinical data, regulatory progress, and launch execution.”</p><p>Also, while high interest rates are a valuation and financing headwind, the market sees the situation as temporary, which according to Citi, will allow IPO momentum to continue.</p><p>Given this http://www.streetinsider.com/Hot+List/U.S.+biotech+SMids%3A+Q3+earnings+preview/27199432.html Sun, 18 Oct 2026 20:00:00 -0400 ABOS AMLX BNTX FTH JAZZ KNSA KYMR MANE MRNA NAMS NUVB NVAX PTGX SRRK VOR http://www.streetinsider.com/Hot+List+Pro/U.S.+biotech+SMids%3A+Q3+earnings+preview/27199432.html <p>Citi is out with its preview into Q3 earnings of U.S. Smid biotech stocks, noting that a continued catalyst calendar and business development engagement have kept investor interest high in this part of the market. The firm has shared with investors key catalysts to watch.</p><p>While conversations on large-cap Biopharma tend to have policy and AI in focus, SMids “offer a more direct investment case around clinical data, regulatory progress, and launch execution.”</p><p>Also, while high interest rates are a valuation and financing headwind, the market sees the situation as temporary, which according to Citi, will allow IPO momentum to continue.</p><p>Given this http://www.streetinsider.com/Hot+List+Pro/U.S.+biotech+SMids%3A+Q3+earnings+preview/27199432.html Sun, 18 Oct 2026 20:00:00 -0400 ABOS AMLX BNTX FTH JAZZ KNSA KYMR MANE MRNA NAMS NUVB NVAX PTGX SRRK VOR http://www.streetinsider.com/Hot+List/U.S.+biotech+SMids%3A+Q3+earnings+preview/27199432.html <p>Citi is out with its preview into Q3 earnings of U.S. Smid biotech stocks, noting that a continued catalyst calendar and business development engagement have kept investor interest high in this part of the market. The firm has shared with investors key catalysts to watch.</p><p>While conversations on large-cap Biopharma tend to have policy and AI in focus, SMids “offer a more direct investment case around clinical data, regulatory progress, and launch execution.”</p><p>Also, while high interest rates are a valuation and financing headwind, the market sees the situation as temporary, which according to Citi, will allow IPO momentum to continue.</p><p>Given this http://www.streetinsider.com/Hot+List/U.S.+biotech+SMids%3A+Q3+earnings+preview/27199432.html Sun, 18 Oct 2026 20:00:00 -0400 ABOS AMLX BNTX FTH JAZZ KNSA KYMR MANE MRNA NAMS NUVB NVAX PTGX SRRK VOR http://www.streetinsider.com/Hot+List+Pro/U.S.+biotech+SMids%3A+Q3+earnings+preview/27199432.html <p>Citi is out with its preview into Q3 earnings of U.S. Smid biotech stocks, noting that a continued catalyst calendar and business development engagement have kept investor interest high in this part of the market. The firm has shared with investors key catalysts to watch.</p><p>While conversations on large-cap Biopharma tend to have policy and AI in focus, SMids “offer a more direct investment case around clinical data, regulatory progress, and launch execution.”</p><p>Also, while high interest rates are a valuation and financing headwind, the market sees the situation as temporary, which according to Citi, will allow IPO momentum to continue.</p><p>Given this http://www.streetinsider.com/Hot+List+Pro/U.S.+biotech+SMids%3A+Q3+earnings+preview/27199432.html Sun, 18 Oct 2026 20:00:00 -0400 ABOS AMLX BNTX FTH JAZZ KNSA KYMR MANE MRNA NAMS NUVB NVAX PTGX SRRK VOR http://www.streetinsider.com/Hot+List/U.S.+biotech+SMids%3A+Q3+earnings+preview/27199432.html <p>Citi is out with its preview into Q3 earnings of U.S. Smid biotech stocks, noting that a continued catalyst calendar and business development engagement have kept investor interest high in this part of the market. The firm has shared with investors key catalysts to watch.</p><p>While conversations on large-cap Biopharma tend to have policy and AI in focus, SMids “offer a more direct investment case around clinical data, regulatory progress, and launch execution.”</p><p>Also, while high interest rates are a valuation and financing headwind, the market sees the situation as temporary, which according to Citi, will allow IPO momentum to continue.</p><p>Given this http://www.streetinsider.com/Hot+List/U.S.+biotech+SMids%3A+Q3+earnings+preview/27199432.html Sun, 18 Oct 2026 20:00:00 -0400 ABOS AMLX BNTX FTH JAZZ KNSA KYMR MANE MRNA NAMS NUVB NVAX PTGX SRRK VOR http://www.streetinsider.com/Hot+List+Pro/U.S.+biotech+SMids%3A+Q3+earnings+preview/27199432.html <p>Citi is out with its preview into Q3 earnings of U.S. Smid biotech stocks, noting that a continued catalyst calendar and business development engagement have kept investor interest high in this part of the market. The firm has shared with investors key catalysts to watch.</p><p>While conversations on large-cap Biopharma tend to have policy and AI in focus, SMids “offer a more direct investment case around clinical data, regulatory progress, and launch execution.”</p><p>Also, while high interest rates are a valuation and financing headwind, the market sees the situation as temporary, which according to Citi, will allow IPO momentum to continue.</p><p>Given this http://www.streetinsider.com/Hot+List+Pro/U.S.+biotech+SMids%3A+Q3+earnings+preview/27199432.html Sun, 18 Oct 2026 20:00:00 -0400 ABOS AMLX BNTX FTH JAZZ KNSA KYMR MANE MRNA NAMS NUVB NVAX PTGX SRRK VOR http://www.streetinsider.com/Hot+List/U.S.+biotech+SMids%3A+Q3+earnings+preview/27199432.html <p>Citi is out with its preview into Q3 earnings of U.S. Smid biotech stocks, noting that a continued catalyst calendar and business development engagement have kept investor interest high in this part of the market. The firm has shared with investors key catalysts to watch.</p><p>While conversations on large-cap Biopharma tend to have policy and AI in focus, SMids “offer a more direct investment case around clinical data, regulatory progress, and launch execution.”</p><p>Also, while high interest rates are a valuation and financing headwind, the market sees the situation as temporary, which according to Citi, will allow IPO momentum to continue.</p><p>Given this http://www.streetinsider.com/Hot+List/U.S.+biotech+SMids%3A+Q3+earnings+preview/27199432.html Sun, 18 Oct 2026 20:00:00 -0400 ABOS AMLX BNTX FTH JAZZ KNSA KYMR MANE MRNA NAMS NUVB NVAX PTGX SRRK VOR http://www.streetinsider.com/Hot+List+Pro/U.S.+biotech+SMids%3A+Q3+earnings+preview/27199432.html <p>Citi is out with its preview into Q3 earnings of U.S. Smid biotech stocks, noting that a continued catalyst calendar and business development engagement have kept investor interest high in this part of the market. The firm has shared with investors key catalysts to watch.</p><p>While conversations on large-cap Biopharma tend to have policy and AI in focus, SMids “offer a more direct investment case around clinical data, regulatory progress, and launch execution.”</p><p>Also, while high interest rates are a valuation and financing headwind, the market sees the situation as temporary, which according to Citi, will allow IPO momentum to continue.</p><p>Given this http://www.streetinsider.com/Hot+List+Pro/U.S.+biotech+SMids%3A+Q3+earnings+preview/27199432.html Sun, 18 Oct 2026 20:00:00 -0400 ABOS AMLX BNTX FTH JAZZ KNSA KYMR MANE MRNA NAMS NUVB NVAX PTGX SRRK VOR http://www.streetinsider.com/Hot+List/U.S.+biotech+SMids%3A+Q3+earnings+preview/27199432.html <p>Citi is out with its preview into Q3 earnings of U.S. Smid biotech stocks, noting that a continued catalyst calendar and business development engagement have kept investor interest high in this part of the market. The firm has shared with investors key catalysts to watch.</p><p>While conversations on large-cap Biopharma tend to have policy and AI in focus, SMids “offer a more direct investment case around clinical data, regulatory progress, and launch execution.”</p><p>Also, while high interest rates are a valuation and financing headwind, the market sees the situation as temporary, which according to Citi, will allow IPO momentum to continue.</p><p>Given this http://www.streetinsider.com/Hot+List/U.S.+biotech+SMids%3A+Q3+earnings+preview/27199432.html Sun, 18 Oct 2026 20:00:00 -0400 ABOS AMLX BNTX FTH JAZZ KNSA KYMR MANE MRNA NAMS NUVB NVAX PTGX SRRK VOR http://www.streetinsider.com/Hot+List+Pro/U.S.+biotech+SMids%3A+Q3+earnings+preview/27199432.html <p>Citi is out with its preview into Q3 earnings of U.S. Smid biotech stocks, noting that a continued catalyst calendar and business development engagement have kept investor interest high in this part of the market. The firm has shared with investors key catalysts to watch.</p><p>While conversations on large-cap Biopharma tend to have policy and AI in focus, SMids “offer a more direct investment case around clinical data, regulatory progress, and launch execution.”</p><p>Also, while high interest rates are a valuation and financing headwind, the market sees the situation as temporary, which according to Citi, will allow IPO momentum to continue.</p><p>Given this http://www.streetinsider.com/Hot+List+Pro/U.S.+biotech+SMids%3A+Q3+earnings+preview/27199432.html Sun, 18 Oct 2026 20:00:00 -0400 ABOS AMLX BNTX FTH JAZZ KNSA KYMR MANE MRNA NAMS NUVB NVAX PTGX SRRK VOR http://www.streetinsider.com/Hot+List/U.S.+biotech+SMids%3A+Q3+earnings+preview/27199432.html <p>Citi is out with its preview into Q3 earnings of U.S. Smid biotech stocks, noting that a continued catalyst calendar and business development engagement have kept investor interest high in this part of the market. The firm has shared with investors key catalysts to watch.</p><p>While conversations on large-cap Biopharma tend to have policy and AI in focus, SMids “offer a more direct investment case around clinical data, regulatory progress, and launch execution.”</p><p>Also, while high interest rates are a valuation and financing headwind, the market sees the situation as temporary, which according to Citi, will allow IPO momentum to continue.</p><p>Given this http://www.streetinsider.com/Hot+List/U.S.+biotech+SMids%3A+Q3+earnings+preview/27199432.html Sun, 18 Oct 2026 20:00:00 -0400 ABOS AMLX BNTX FTH JAZZ KNSA KYMR MANE MRNA NAMS NUVB NVAX PTGX SRRK VOR http://www.streetinsider.com/Hot+List+Pro/U.S.+biotech+SMids%3A+Q3+earnings+preview/27199432.html <p>Citi is out with its preview into Q3 earnings of U.S. Smid biotech stocks, noting that a continued catalyst calendar and business development engagement have kept investor interest high in this part of the market. The firm has shared with investors key catalysts to watch.</p><p>While conversations on large-cap Biopharma tend to have policy and AI in focus, SMids “offer a more direct investment case around clinical data, regulatory progress, and launch execution.”</p><p>Also, while high interest rates are a valuation and financing headwind, the market sees the situation as temporary, which according to Citi, will allow IPO momentum to continue.</p><p>Given this http://www.streetinsider.com/Hot+List+Pro/U.S.+biotech+SMids%3A+Q3+earnings+preview/27199432.html Sun, 18 Oct 2026 20:00:00 -0400 ABOS AMLX BNTX FTH JAZZ KNSA KYMR MANE MRNA NAMS NUVB NVAX PTGX SRRK VOR http://www.streetinsider.com/Hot+List/U.S.+biotech+SMids%3A+Q3+earnings+preview/27199432.html <p>Citi is out with its preview into Q3 earnings of U.S. Smid biotech stocks, noting that a continued catalyst calendar and business development engagement have kept investor interest high in this part of the market. The firm has shared with investors key catalysts to watch.</p><p>While conversations on large-cap Biopharma tend to have policy and AI in focus, SMids “offer a more direct investment case around clinical data, regulatory progress, and launch execution.”</p><p>Also, while high interest rates are a valuation and financing headwind, the market sees the situation as temporary, which according to Citi, will allow IPO momentum to continue.</p><p>Given this http://www.streetinsider.com/Hot+List/U.S.+biotech+SMids%3A+Q3+earnings+preview/27199432.html Sun, 18 Oct 2026 20:00:00 -0400 ABOS AMLX BNTX FTH JAZZ KNSA KYMR MANE MRNA NAMS NUVB NVAX PTGX SRRK VOR http://www.streetinsider.com/Hot+List+Pro/U.S.+biotech+SMids%3A+Q3+earnings+preview/27199432.html <p>Citi is out with its preview into Q3 earnings of U.S. Smid biotech stocks, noting that a continued catalyst calendar and business development engagement have kept investor interest high in this part of the market. The firm has shared with investors key catalysts to watch.</p><p>While conversations on large-cap Biopharma tend to have policy and AI in focus, SMids “offer a more direct investment case around clinical data, regulatory progress, and launch execution.”</p><p>Also, while high interest rates are a valuation and financing headwind, the market sees the situation as temporary, which according to Citi, will allow IPO momentum to continue.</p><p>Given this http://www.streetinsider.com/Hot+List+Pro/U.S.+biotech+SMids%3A+Q3+earnings+preview/27199432.html Sun, 18 Oct 2026 20:00:00 -0400 ABOS AMLX BNTX FTH JAZZ KNSA KYMR MANE MRNA NAMS NUVB NVAX PTGX SRRK VOR http://www.streetinsider.com/Hot+List/U.S.+biotech+SMids%3A+Q3+earnings+preview/27199432.html <p>Citi is out with its preview into Q3 earnings of U.S. Smid biotech stocks, noting that a continued catalyst calendar and business development engagement have kept investor interest high in this part of the market. The firm has shared with investors key catalysts to watch.</p><p>While conversations on large-cap Biopharma tend to have policy and AI in focus, SMids “offer a more direct investment case around clinical data, regulatory progress, and launch execution.”</p><p>Also, while high interest rates are a valuation and financing headwind, the market sees the situation as temporary, which according to Citi, will allow IPO momentum to continue.</p><p>Given this http://www.streetinsider.com/Hot+List/U.S.+biotech+SMids%3A+Q3+earnings+preview/27199432.html Sun, 18 Oct 2026 20:00:00 -0400 ABOS AMLX BNTX FTH JAZZ KNSA KYMR MANE MRNA NAMS NUVB NVAX PTGX SRRK VOR http://www.streetinsider.com/Hot+List+Pro/U.S.+biotech+SMids%3A+Q3+earnings+preview/27199432.html <p>Citi is out with its preview into Q3 earnings of U.S. Smid biotech stocks, noting that a continued catalyst calendar and business development engagement have kept investor interest high in this part of the market. The firm has shared with investors key catalysts to watch.</p><p>While conversations on large-cap Biopharma tend to have policy and AI in focus, SMids “offer a more direct investment case around clinical data, regulatory progress, and launch execution.”</p><p>Also, while high interest rates are a valuation and financing headwind, the market sees the situation as temporary, which according to Citi, will allow IPO momentum to continue.</p><p>Given this http://www.streetinsider.com/Hot+List+Pro/U.S.+biotech+SMids%3A+Q3+earnings+preview/27199432.html Sun, 18 Oct 2026 20:00:00 -0400 ABOS AMLX BNTX FTH JAZZ KNSA KYMR MANE MRNA NAMS NUVB NVAX PTGX SRRK VOR http://www.streetinsider.com/Hot+List/U.S.+biotech+SMids%3A+Q3+earnings+preview/27199432.html <p>Citi is out with its preview into Q3 earnings of U.S. Smid biotech stocks, noting that a continued catalyst calendar and business development engagement have kept investor interest high in this part of the market. The firm has shared with investors key catalysts to watch.</p><p>While conversations on large-cap Biopharma tend to have policy and AI in focus, SMids “offer a more direct investment case around clinical data, regulatory progress, and launch execution.”</p><p>Also, while high interest rates are a valuation and financing headwind, the market sees the situation as temporary, which according to Citi, will allow IPO momentum to continue.</p><p>Given this http://www.streetinsider.com/Hot+List/U.S.+biotech+SMids%3A+Q3+earnings+preview/27199432.html Sun, 18 Oct 2026 20:00:00 -0400 ABOS AMLX BNTX FTH JAZZ KNSA KYMR MANE MRNA NAMS NUVB NVAX PTGX SRRK VOR http://www.streetinsider.com/Hot+List+Pro/U.S.+biotech+SMids%3A+Q3+earnings+preview/27199432.html <p>Citi is out with its preview into Q3 earnings of U.S. Smid biotech stocks, noting that a continued catalyst calendar and business development engagement have kept investor interest high in this part of the market. The firm has shared with investors key catalysts to watch.</p><p>While conversations on large-cap Biopharma tend to have policy and AI in focus, SMids “offer a more direct investment case around clinical data, regulatory progress, and launch execution.”</p><p>Also, while high interest rates are a valuation and financing headwind, the market sees the situation as temporary, which according to Citi, will allow IPO momentum to continue.</p><p>Given this http://www.streetinsider.com/Hot+List+Pro/U.S.+biotech+SMids%3A+Q3+earnings+preview/27199432.html Sun, 18 Oct 2026 20:00:00 -0400 ABOS AMLX BNTX FTH JAZZ KNSA KYMR MANE MRNA NAMS NUVB NVAX PTGX SRRK VOR